Novo Nordisk's Pill, Ryanair Fined, Akzonobel's Activist | Stock Movers
December 23, 2025
162
2
1.23%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Bloomberg Podcasts Episodes Around December 23, 2025
See what was published immediately before and after this episode.
4:47Now PlayingNovo Nordisk's Pill, Ryanair Fined, Akzonobel's Activist | Stock Movers
YouTube Description
as posted by the channelOn This episode of Stock Movers:
- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.
- Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies.
- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Novo Nordisk's Pill, Ryanair Fined, Akzonobel's Activist
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.